29/01/2026 – AB Science announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance (NOA) for a patent relating to methods of treating metastatic castrate resistant prostate cancer (mCRPC) Download PDF Post navigationPreviousPrevious post:AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041NextNext post:FDA granted the status of Minor Use in Major Species (MUMS) for Masivet®Related PostsAB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs10 July 2026AB Science’s Board of Directors is restructuring its governance to usher in a new phase in the company’s development8 July 2026AB Science announces the successful completion of a EUR 2.3 million private placement1 July 2026AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML29 June 2026AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 204217 June 2026AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS9 June 2026
AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs10 July 2026
AB Science’s Board of Directors is restructuring its governance to usher in a new phase in the company’s development8 July 2026
AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML29 June 2026
AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 204217 June 2026
AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS9 June 2026
